Potvin JM et al 99 Potvin JM, Rodes-Cabau J, Bertrand OF, Gleeton O, Nguyen CN, Barbeau G, et al. Usefulness of fractional flow reserve measurements to defer revascularisation in patients with stable or unstable angina pectoris, non ST-elevation and ST-elevation myocardial infarction, or atypical chest pain. Am J Cardiol. 2006;98(3):289-97.
|
2006 |
11 ± 6 months |
Retrospective cohort |
201 |
62 ± 10 |
131 |
61 |
124 |
11 |
113 |
≥ 0.75 |
24 hours (range 2 to 144) |
NR |
intracoronary administration of adenosine (median dose 60 µg, range 30 to 300, for the left coronary artery and 30 µg, range 18 to 120, for the right coronary artery) and/or nitroprusside (median dose 250 µg, range 100 to 1,000, for the left and right coronary arteries). Intracoronary adenosine was used in 135 cases, intracoronary nitroprusside in 14 cases, and adenosine andnitroprusside in 52 cases |
Patients within 24 hours of acute STEMI were excluded |
Fischer J et al 88 Fischer JJ, Wang XQ, Samady H, Sarembock IJ, Powers ER, Gimple LW, et al. Outcome of patients with acute coronary syndromes and moderate coronary lesions undergoing deferral of revascularisation based on fractional flow reserve assessment. Catheter Cardiovasc Interv. 2006;68(4):544-8.
|
2006 |
12 months |
Retrospective cohort |
111 |
ACS → 58 ± 14Non-ACS → 63 ± 10 |
72 |
76 |
35 |
11 |
24 |
≥ 0.75 |
Recent(within 7 days) ST segment elevation MI treated with lytic Therapy |
ACS → 9Non-ACS → 9 |
intracoronary adenosine (30 µg bolus in the right coronary artery or 40-60 µg bolus in the left coronary artery |
NR |
Sels et al 2424 Sels JW, Tonino PA, Siebert U, Fearon WF, Van't Veer M, De Bruyne B, et al. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus angiography for Multivessel evaluation) study. JACC Cardiovasc Interv. 2011;4(11):1183-9.
|
2011 |
2 years |
Prospective cohort |
1005 |
ACS → 64.8 ± 10.7Non-ACS → 64.3 ± 10 |
744 |
677 |
328 |
0 |
328 |
≥ 0.80 |
NR |
NR |
Intravenous adenosine, administered at a rate of 140 µg/kg/min through a central vein. |
Exclusion criteria were left main disease, previous CABG, and STEMI < 5 days before, because the use of FFR is not validated in recent STEMI. Patients admitted for UA and NSTEMI with positive troponin but total creatine kinase < 1,000 U/l could be included |
Mehta et al 2525 Masrani Mehta S, Depta JP, Novak E, Patel JS, Patel Y, Raymer D, et al. Association of lower fractional flow reserve values with higher risk of adverse cardiac events for lesions deferred revascularization among patients with acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002172.
|
2015 |
3.4 ± 1.6 years |
Retrospective cohort |
674 |
ACS → 63.8 ± 11.9Non-ACS → 65.3 ± 10.2 |
380 |
340 |
334 |
7 |
327 |
> 0.80 |
NR |
ACS → 221Non-ACS → 209 |
Predominant use of intracoronary adenosine with similar maximum doses for both groups (120 µg) |
NR |
Hakeem A et al 3434 Hakeem A, Edupuganti MM, Almomani A, Pothineni NV, Payne J, Abualsuod AM, et al. Long-term prognosis of deferred acute coronary syndrome lesions based on nonischemic fractional flow reserve. Am Coll Cardiol. 2016;68(11):1181-91.
|
2016 |
3,4 ± 1,6 anos |
Retrospective cohort |
576 |
ACS → 66.6 ± 8Non-ACS → 64.7 ± 8.7 |
554 |
370 |
206 |
0 |
206 |
> 0.75 |
NR |
ACS → 135Non-ACS → 216 |
Intravenous (140 mg/kg/min) or intracoronary (at least 60 mg) adenosine. The median dose of intracoronary adenosine in our cohort was 130 mg |
NR |
Van Belle et al 3838 Van Belle E, Baptista SB, Raposo L, Henderson J, Rioufol G, Santos L, et al; PRIME-FFR Study Group. Impact of Routine Fractional Flow Reserve on Management Decision and 1-Year Clinical Outcome of Patients With Acute Coronary Syndromes: PRIME-FFR (Insights From the POST-IT [Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary Disease] and R3F [French FFR Registry] Integrated Multicenter Registries - Implementation of FFR [Fractional Flow Reserve] in Routine Practice). Circ Cardiovasc Interv. 2017; 10(6). pii: e004296
|
2017 |
1 year |
Retrospective cohort |
958 |
ACS → 66 ± 11.2Non-ACS → 66.4 ± 10 |
693 |
721 |
237 |
- |
- |
> 0.75 e > 0.80 |
NR |
NR |
NR |
NR |
Lee JM et al 3737 Lee JM, Choi KH, Koo BK, Shin ES, Nam CW, Doh JH, et al. Prognosis of deferred non-culprit lesions according to fractional flow reserve in patients with acute coronary syndrome. Eurointervention. 2017;13(9):e1112-9.
|
2017 |
722 days |
Retrospective cohort |
1596 |
ACS → 62.0 ± 11.1Non-ACS → 62.4 ± 9.4 |
1112 |
1295 |
301 |
0 |
301 |
> 0.80 |
NR |
NR |
Hyperemia was induced with an intracoronary bolus administration (80 µg in left coronary artery, 40 µg in right coronary artery), intracoronary (240 µg/min) or, iv continuous infusion (140 µg/Kg/min) of adenosine. |
NR |